NYSE:PFE

Pfizer Inc (PFE)

25.76
+0.42 (1.64%)
as of Jun 4, 2026, 2:38:43 pm Market Open.
579 watching
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO

Most recent Opinions go here

Be up to date, don't miss your chance.

DON'T BUY

They face a patent cliff. Are buying companies and working on their drug pipeline to offset that, but this is their main problem. Little growth is expected in coming years. Pays an attractive yield and trades at a low PE, though.

DON'T BUY

It has no earnings momentum. You get only the 6.66% dividend.

HOLD
Investor's down. Sell, add more, or just wait?

Attractive dividend. More of a marketing engine (and it's been really successful) than a drug development company. Once that Iran conflict trade comes off, defensives will be likely recipients. If you own, he probably wouldn't sell here; keep collecting the dividend, and perhaps sell later on strength.

Not everything in your portfolio will be going gangbusters at all times. Leadership rotates and takes turns.

BUY

It pays a yield of 6.4% and has a good pipeline of drugs in development.

HOLD

Wasted $$ after the pandemic. Now refocused. Blockbuster drugs are tapped out, needs a new one. They will find one, and you could make a lot of money.

Meanwhile, you collect the yield of 7% (which is probably good for the next 3 years). If they don't find a monster drug by then, dividend will probably be cut. He's taking the risk.

DON'T BUY

Hit their patent cliffs PFE is cutting costs, but that goes only so far. Prefers other areas of healthcare.

DON'T BUY

 It reports Tuesday. Pays a great dividend, but doesn't see a blockbuster drug to move the needle. 

Unspecified

It over-earned during Covid which was not sustainable. It is trying to make up for lost revenue now. It is a high quality company but needs a near term catalyst. Its pipeline investments will take a while. Dividend yield is attractive. Look for more attractive health care companies with both dividend and growth opportunities.

DON'T BUY

Better stocks in pure pharma. PFE has little in their pipeline. Any gains they make will be in cutting costs or buying a company. 

DON'T BUY

Trading at 8-9x PE. Problem (as for many pharma companies) is that the drugs that make the most amount of $$ are social drugs (Prozac, weight loss) rather than drugs that solve the actual problem (each cancer drug is very niche). Historically, traded at high multiples because people thought they were growth companies; but pharma is not as growthy as people thought. Yield is 6%.

He owns NVO and LLY, and those are his preferences. Drugs with these two will generate lots of money over the next few years.

BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

PFE is very cheap at 8X earnings with a 6.78% dividend. But it has been cheap for a while. It still has uncertainty over Covid revenue, and its full year guidance raise (2.5%) was not so impressive. EPS is still expected to fall marginally in 2026 ($3.11 to $3.00). With lower interest rates ahead (probably) and a possible economic slowdown (always possible) and possible sector rotation, there will come a time when the stock performs much better. We would of course like to see higher growth. For patient investors, we think it is buyable, but we would stress the need for patience here. The government push towards lower drug prices may keep sentiment negative for a longer period of time.
Unlock Premium - Try 5i Free

HOLD

Little momentum, good dividend, but didn't like their update yesterday. A weak hold.

WAIT

This bottomed with the market in April and has risen with the mark since then. He wants to see this break $26; if so, it will take off. Be patient. Most money is made by sitting on your hands.

HOLD

They have a lot of irons in the fire and pay a 6.8% dividend yield.

BUY

Pays a 6.9% dividend. The Covid vaccine days are long gone, so shares have been stuck around $25 for months. So, you still get a decent return from the dividend. Pfizer has been buying companies in recent companies, like Seagen, so they can build a powerful drug pipeline to offsets patent expirations. 

Showing 1 to 15 of 883 entries

Pfizer Inc (PFE) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE (previously PFE-N on Stockchase) on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE

Is Pfizer Inc a buy or a sell?

In the last year, 24 stock analysts published opinions about PFE (previously PFE-N on Stockchase). 7 analysts recommended to BUY the stock. 13 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by Jim Cramer - Mad Money on 2025-11-21. Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

24 stock analysts on Stockchase covered Pfizer Inc in the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2026-06-04, Pfizer Inc (PFE) stock closed at a price of $25.76.